"Copernicus" Amivantamab + Lazertinib or Chemo for EGFR-Mutated NSCLC (Non-Small Cell Lung Cancer)

This study consists of 2 cohorts, Cohort 1 and Cohort 2. Cohort 1 If you choose to join this study and take part in Cohort 1, you will:

• Get the study drug as an injection (shot under the skin)
• Take lazertinib tablets once each day
• Take an an oral or injectable medication during the first 4 months of study drug to prevent or reduce the likelihood and severity of blood clots
• Take medications to prevent the known possible side effects of the study drug and lazertinib (e.g., skin and/or nail rash)

Cohort 2 If you choose to join this study and take part in Cohort 2, you will:

• Get the study drug as an injection (shot under the skin)
• Get chemotherapy (carboplatin and pemetrexed)
• Take medications to prevent the known possible side effects of the study drug (e.g., skin and/or nail rash)

During the study visits the following procedures may occur: physical exam, vital signs, electrocardiograms, tumor imaging (CT/MRI), questionnaires, blood draws, and tumor biopsy. The duration of your involvement in the study will vary depending on how you and your disease respond to the study drug. Participation might last as long as 3 years. During the first year, you can expect to visit the study site around 20 times. Afterward, visits will occur every 3 weeks until you stop the study regimen. Following that, visits will be scheduled every 12 weeks until the study concludes.